Literature DB >> 21256451

The risky business of drug development in neurology.

Rebecca Craven.   

Abstract

Mesh：

Year:  2011        PMID： 21256451     DOI： 10.1016/S1474-4422(11)70004-7

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  3 in total

Review 1.  The future of the pharmaceutical sciences and graduate education: recommendations from the AACP Graduate Education Special Interest Group.

Authors:  Susanna Wu-Pong; Jogarao Gobburu; Stephen O'Barr; Kumar Shah; Jason Huber; Daniel Weiner
Journal:  Am J Pharm Educ       Date:  2013-05-13       Impact factor: 2.047

2.  Fire in the ashes: can failed Alzheimer's disease drugs succeed with second chances?

Authors:  Robert E Becker; Nigel H Greig
Journal:  Alzheimers Dement       Date:  2012-03-30       Impact factor: 21.566

Review 3.  Epigenetic pharmacotherapy for substance use disorder.

Authors:  Gregory C Sartor
Journal:  Biochem Pharmacol       Date:  2019-07-12       Impact factor: 5.858
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.